FreeTheAI

Profound Medical Shares New Clinical Data Supporting TULSA Prostate Treatment

BullishMedium impact
PRNCA$9.99 1.63%

Profound Medical Corp. (TSX:PRN) released new clinical and real-world data evaluating its TULSA procedure for prostate treatment. Results from the CAPTAIN randomized controlled trial demonstrated functional advantages for TULSA over robotic radical prostatectomy at six months, alongside lower complication-related hospitalizations of 0.7% compared to 6.3% for traditional surgery. Additional real-world data from Mayo Clinic sites in Florida highlighted a 100% pad-free continence rate and 87.5% erection preservation rate, while whole-gland data from the CARE Registry achieved a PSA nadir of 0.23 ng/mL.

These findings support the clinical benefits of TULSA by showing reduced side effects and fewer hospital readmissions relative to invasive surgery. Preserving sexual function and urinary continence remains a major factor for patients choosing prostate therapies. Furthermore, demonstrating technical feasibility on Siemens 0.55T MRI systems indicates potential to expand the procedure to lower-cost, wide-bore MRI platforms. Shares of Profound Medical Corp rose 1.63% to 9.99 CAD following the update.

Investors and healthcare providers will look for longer-term oncology results to confirm cancer control outcomes over extended periods. Market adoption will also depend on securing broader insurance reimbursement coverage and achieving formal regulatory and commercial milestones for deployment on lower-field MRI equipment.

Key points

  • CAPTAIN trial data showed superior functional outcomes for TULSA over robotic surgery at six months.
  • Complication-related hospitalizations were 0.7% for TULSA compared to 6.3% for robotic radical prostatectomy.
  • Real-world data from Mayo Clinic in Florida demonstrated 100% pad-free continence and 87.5% erection preservation.
  • CARE Registry whole-gland ablation results showed a PSA nadir of 0.23 ng/mL.
  • Testing confirmed technical feasibility on lower-cost Siemens 0.55T MRI systems.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did the new trial data show for Profound Medical's TULSA procedure?

The CAPTAIN study showed TULSA provided better six-month functional outcomes and a lower hospitalization rate of 0.7% versus 6.3% for robotic radical prostatectomy.

What real-world outcomes were reported from Mayo Clinic sites?

Data from Mayo Clinic in Florida showed patients achieved a 100% pad-free continence rate and preserved erections in 87.5% of cases following treatment.

Can TULSA be used on lower-cost MRI platforms?

Testing confirmed technical feasibility on Siemens 0.55T wide-bore MRI systems, suggesting potential for broader platform adoption.